Serum NY-ESO-1 and P53 Antibodies As Useful Tumor Markers in Gastric Cancer

Overview

Journal Ann Gastroenterol Surg

Date 2024 Mar 8

PMID 38455491

Authors

Junji Kawada

Takuro Saito

Yukinori Kurokawa

Ryohei Kawabata

Atsushi Takeno

Tomohira Takeoka

Yohei Nose

Hisashi Wada

Hidetoshi Eguchi

Yuichiro Doki

Affiliations

Soon will be listed here.

Abstract

Purpose: The NY-ESO-1 antigen is highly immunogenic and often spontaneously induces an immune response in patients with cancer. We conducted a large-scale multicenter cohort study to investigate the utility of serum NY-ESO-1 and p53 antibodies as predictive markers for the postoperative recurrence of gastric cancer. Here, we examined the usefulness of pre-treatment NY-ESO-1 and p53 antibodies as tumor markers for the diagnosis of gastric cancer in combination with carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).

Methods: A total of 1031 patients with cT3-4 gastric cancer were enrolled in the study. NY-ESO-1 and p53 antibodies were assessed prior to treatment. The positivity of NY-ESO-1 and p53 antibodies, CEA, and CA19-9 was evaluated before treatment.

Results: Serum NY-ESO-1 and p53 antibodies were positive in 12.6% and 18.1% of the patients, respectively. Positive NY-ESO-1 antibody response was correlated with male gender, higher cStage, and upper tumor location. However, a positive p53 antibody response was not associated with tumor factors. The combination of NY-ESO-1 or p53 antibody response with CEA and CA19-9, or the 4-factors, was positive in 45.1%, 49.6%, and 53.8% of patients, respectively. Moreover, the 4-factor combination was able to detect >60% of cStage III-IV diseases, which was 14% higher than that with the combination of CEA and CA19-9.

Conclusion: The combination of NY-ESO-1 and p53 antibody responses to CEA and CA19-9 increases the diagnostic accuracy of gastric cancer. Serum NY-ESO-1 and p53 antibodies may be useful tumor markers for gastric cancer.

Citing Articles

Rationale for Testing TP53 Mutations in Thyroid Cancer-Original Data and Meta-Analysis.

Lacka K, Maciejewski A, Tyburski P, Manuszewska-Jopek E, Majewski P, Wieckowska B Int J Mol Sci. 2025; 26(3).

PMID: 39940804 PMC: 11817394. DOI: 10.3390/ijms26031035.

Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.

Kawada J, Saito T, Kurokawa Y, Kawabata R, Takeno A, Takeoka T Ann Gastroenterol Surg. 2024; 8(2):243-250.

PMID: 38455491 PMC: 10914697. DOI: 10.1002/ags3.12757.

References

Tsuji T, Gnjatic S . Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy. Oncoimmunology. 2012; 1(3):405-407. PMC: 3382850. DOI: 10.4161/onci.19310. View

Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y . Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003; 133(1):24-31. DOI: 10.1067/msy.2003.31. View

Fujita S, Wada H, Jungbluth A, Sato S, Nakata T, Noguchi Y . NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res. 2004; 10(19):6551-8. DOI: 10.1158/1078-0432.CCR-04-0819. View

. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14(2):113-23. DOI: 10.1007/s10120-011-0042-4. View

Zhang Z, Li F, Lu M, Zhang S, Li Y . Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma. Oncotarget. 2017; 8(61):103283-103289. PMC: 5732727. DOI: 10.18632/oncotarget.22464. View

Kim M, Lozano G . Mutant p53 partners in crime. Cell Death Differ. 2017; 25(1):161-168. PMC: 5729539. DOI: 10.1038/cdd.2017.185. View

Shimada H . p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2018; 2(4):266-273. PMC: 6036386. DOI: 10.1002/ags3.12179. View

Francis D, Manspeaker M, Schudel A, Sestito L, OMelia M, Kissick H . Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med. 2020; 12(563). PMC: 8377700. DOI: 10.1126/scitranslmed.aay3575. View

Chen Y, Scanlan M, Sahin U, Tureci O, Gure A, Tsang S . A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94(5):1914-8. PMC: 20017. DOI: 10.1073/pnas.94.5.1914. View

10.

STOCKERT E, Jager E, Chen Y, Scanlan M, Gout I, Karbach J . A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998; 187(8):1349-54. PMC: 2212223. DOI: 10.1084/jem.187.8.1349. View

11.

Kawada J, Saito T, Kurokawa Y, Kawabata R, Takeno A, Takeoka T . Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer. Ann Gastroenterol Surg. 2024; 8(2):243-250. PMC: 10914697. DOI: 10.1002/ags3.12757. View

12.

Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N . Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 1994; 54(7):1766-71. View

13.

Yamashita K, Hosoda K, Niihara M, Hiki N . History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg. 2021; 5(4):446-456. PMC: 8316740. DOI: 10.1002/ags3.12439. View

14.

Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H . The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003; 6(3):142-5. DOI: 10.1007/s10120-003-0240-9. View

15.

Gnjatic S, Nishikawa H, Jungbluth A, Gure A, Ritter G, Jager E . NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30. DOI: 10.1016/S0065-230X(06)95001-5. View

16.

Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y . Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2013; 17(1):26-33. DOI: 10.1007/s10120-013-0259-5. View

17.

Oshima Y, Shimada H, Yajima S, Nanami T, Matsushita K, Nomura F . NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol. 2015; 51(1):30-4. DOI: 10.1007/s00535-015-1078-8. View

18.

Hoshino I, Nabeya Y, Takiguchi N, Gunji H, Ishige F, Iwatate Y . Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers. Ann Gastroenterol Surg. 2020; 4(3):275-282. PMC: 7240143. DOI: 10.1002/ags3.12325. View

19.

Sakai Y, Kurose K, Sakaeda K, Abo H, Atarashi Y, Ide N . A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. Clin Chim Acta. 2021; 519:51-59. DOI: 10.1016/j.cca.2021.04.008. View

20.

Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F . Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995; 63(3):375-80. DOI: 10.1002/ijc.2910630313. View